Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN5001 in pulmonary nodules
NCT07185035Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5001 in lung neoplasm, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of all adverse events at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
KN5001
03
Conditions
lung neoplasm
Beyond the preview
Go deeper on NCT07185035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185035.